环氧化酶-2 在人乳腺癌中的表达：与 HER-2/neu 及其他临床病理预后因素的关系。

Expression of cyclooxygenase-2 in human breast cancer: relationship with HER-2/neu and other clinicopathological prognostic factors.

机构信息

Ewha Medical Research Center, Department of Internal Medicine, Seoul, Korea.

出版信息

Cancer Res Treat. 2005 Jun;37(3):165-70. doi: 10.4143/crt.2005.37.3.165. Epub 2005 Jun 30.

DOI:10.4143/crt.2005.37.3.165

PMID:19956498

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2785410/

Abstract

PURPOSE

Previous epidemiologic studies have demonstrated that nonsteroidal anti-inflammatory drugs can reduce the risk of breast cancer, and this possibly happens via cyclooxygenase (COX) inhibition. Moreover, growth factor-inducible COX-2, which is overexpressed in neoplastic tissue, is an attractive therapeutic target. Thus, we evaluated the expression of COX-2 in breast cancer tissues, and we assessed the association between COX-2 expression and HER-2/neu expression and also with several clinicopathological features.

MATERIALS AND METHODS

We analyzed the surgical specimens from 112 women with breast cancer who had undergone lumpectomy or mastectomy. The expressions of COX-2, HER-2/neu, MMP-2 and TIMP-2 were determined immunohistochemically. The correlations between COX-2 expression and several variables, including clinicopathological factors, HER-2/neu expression, MMP-2 expression and TIMP-2 expression were analyzed. Survival analysis was also performed with respect to COX-2 overexpression.

RESULTS

The overexpression of COX-2 protein was observed in 28.6% of the breast cancer tissues. Tumors with lymph node metastasis more frequently showed COX-2 overexpression than did those tumors without metastasis (p=0.039), and the increased COX-2 expression correlated positively with HER-2/neu overexpression (p=0.000). No significant differences were found for the MMP-2 or TIMP-2 expression rates in the COX-2 positive and negative groups. The survival analysis revealed no significant differences according to the COX-2 expression.

CONCLUSION

This study results suggest that increased COX-2 expression is related with the progression of breast cancer, e.g., with lymph node invasion. COX-2 overexpression found to be related with HER-2/neu overexpression, but not with MMP-2 or TIMP-2 expression. These results support the potential use of selective agents that inhibit COX-2 or HER-2/neu for the management of breast cancer.

摘要

目的

先前的流行病学研究表明，非甾体抗炎药可以降低乳腺癌的风险，这可能是通过环氧化酶（COX）抑制作用实现的。此外，在肿瘤组织中过表达的生长因子诱导型 COX-2 是一个有吸引力的治疗靶点。因此，我们评估了 COX-2 在乳腺癌组织中的表达，并评估了 COX-2 表达与 HER-2/neu 表达之间的关系，以及与几个临床病理特征之间的关系。

材料与方法

我们分析了 112 例接受乳房肿块切除术或乳房切除术的乳腺癌女性患者的手术标本。免疫组织化学法检测 COX-2、HER-2/neu、MMP-2 和 TIMP-2 的表达。分析 COX-2 表达与包括临床病理因素、HER-2/neu 表达、MMP-2 表达和 TIMP-2 表达在内的几个变量之间的相关性。还对 COX-2 过表达与生存的关系进行了生存分析。

结果

在 28.6%的乳腺癌组织中观察到 COX-2 蛋白过表达。有淋巴结转移的肿瘤比无转移的肿瘤更常出现 COX-2 过表达（p=0.039），并且 COX-2 表达的增加与 HER-2/neu 过表达呈正相关（p=0.000）。COX-2 阳性和阴性组的 MMP-2 或 TIMP-2 表达率无显著差异。生存分析显示，COX-2 表达与生存率无显著关系。